Dear Editor,

In the current era of personalised cancer treatment and targeted therapy, the role of biomarkers in cancer management is becoming unquestionable. Immunotherapy is gradually revolutionising bladder cancer (BC) management with positive results from major trials in the treatment of muscle-invasive BC (MIBC) and metastatic BC [1]. Moreover, both the Southwest Oncology Group (SWOG) 8710 trial [2], as well as the more recent PURE-01 trial (ClinicalTrials.gov Identifier: NCT02736266) [3], showed a high complete response rate of nearly 40% for neoadjuvant pembrolizumab immunotherapy. However, the toxicity and the high financial cost of these drugs, plus the development of resistance to these agents, highlight the need to identify and develop prognostic and predictive biomarkers in order to maximise therapeutic effects in a small number of patients. To this extent, both United States Food and Drug Administration (FDA)-approved programmed cell death protein ligand 1 (PD-L1) and fibroblast growth factor receptors (FGFRs) have been studied as useful biomarkers for predicting the efficacy of immune checkpoint inhibitors in BC. Additionally, a recent literature review published in this journal by Nowak et al. [4] found an association between increased PD-L1 expression and BCG unresponsiveness in non-MIBC (NMIBC). Unfortunately, current evidence is inconsistent and incorporating these biomarkers into clinical practice is still premature, with further multicentre randomised trials needed to make definitive conclusions.

In this issue of the Arab Journal of Urology, Agrawal et al. [5] explored the prognostic and therapeutic potential of a third biomarker for BC: the human epidermal growth factor receptor 2 (HER2), a tyrosine kinase transmembrane receptor involved in cycle cell regulation and cell proliferation. While previous authors studied HER2 as a potential therapeutic target in MIBC, HER2 expression and gene amplification in NMIBC was still unclear [6]. In their retrospective analysis of 93 BCs (25 MIBC and 68 NMIBC), three results should be highlighted: (i) the HER2 protein expression by immunohistochemistry correlated with the stage and grade of BC, (ii) progression-free survival significantly correlated with stage, grade and HER2 3+ expression, and (iii) that in the NMIBC subgroup, HER2 3+ expression and gene amplification was seen only in high-grade NMIBC, all of them being lamina-invasive (pT1). Firstly, these results confirm the prognostic value of HER2, as opposed to the Kumar et al. [7] study where HER2 overexpression was not correlated with staging, lymph node metastasis or recurrence of the disease. Secondly, they showed that about one-half of non-invasive tumours show high-grade histology and HER2 3+ protein expression on immunohistochemistry, therefore paving the way for HER2 gene amplification by fluorescent in situ hybridisation in all HER2 3+ high-grade NMIBC.

Clinical implications of this study are remarkable: in addition to its prognostic role in BC, HER2 amplification in MIBC and high-grade NMIBC makes HER2-targeted therapy a possible treatment modality in such patients. Multiple clinical trials using lapatinib, a potent HER1 and HER2 inhibitor, or trastuzumab, as treatments for locally advanced or metastatic BC, failed to show relevant anti-tumour activity [8,9]. But data on the efficacy of HER2-targeted therapy on high-grade MIBC is lacking and should be studied. There are actually three clinical trials evaluating the efficacy of trastuzumab (NCT04482309); PRS-343, which is a bispecific fusion protein of anti-HER2 monoclonal antibody/anti-CD137 anti-calin (NCT03330561); and PRS-343 in combination with atezolizumab (NCT03650348) in HER2-positive solid tumours, including urothelial carcinoma. These trials might give us more insight and evidence on the use of HER2-targeted therapy in treating BC.

Overall, the study here contributes valuable data in steadily improving our understanding of HER2 expression in BC. Further prospective studies, as well as ongoing trials on HER2-targeted therapy, will certainly shed more light on the role of HER2 in BC management and treatment.

Disclosure statement

The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

References

[1] Wołącewicz M, Hrynkiewicz R, Grywalska E, et al. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers (Basel). 2020;12:1181.
[2] Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with
cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.

[3] Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, Phase II study. J Clin Oncol. 2018;36:3353–3360.

[4] Nowak Ł, Krajewski W, Poterek A, et al. The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guerin immunotherapy: current status. Arab J Urol. 2020;1–4. [Epub ahead of print]. DOI:10.1080/2090598X.2020.1791562

[5] Agrawal V, Bharti N, Pandey R. Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: identification of patients for targeted therapy. Arab J Urol. 2020;1–6. [Epub ahead of print]. DOI:10.1080/2090598X.2020.1814183

[6] Hegazy R, Kamel M, Salem EA, et al. The prognostic significance of p53, p63 and Her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–Guerin. Arab J Urol. 2015;13:225–230.

[7] Kumar S, Prajapati O, Vaiphei K, et al. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: is it worth hype? South Asian J Cancer. 2015;4:115–117.

[8] Wülfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115:2881–2890.

[9] Oudard S, Culine S, Vano Y, et al. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2015;51:45–54.

Julien Sarkis
Department of Urology, Hotel-Dieu deFrance Hospital, Beirut, Lebanon
juliensarkis@live.com
http://orcid.org/0000-0002-5060-0819

Marwan Alkassis
Department of Urology, Hotel-Dieu deFrance Hospital, Beirut, Lebanon

Joy Assaf
Department of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon